- Home
- INZY vs CCRD Comparison
INZY vs CCRD Comparison
Compare INZY & CCRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- CCRD
- Stock Information
- Founded
- INZY 2015
- CCRD 1973
- Country
- INZY United States
- CCRD United States
- Employees
- INZY N/A
- CCRD N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- CCRD
- Sector
- INZY Health Care
- CCRD
- Exchange
- INZY Nasdaq
- CCRD Nasdaq
- Market Cap
- INZY 188.2M
- CCRD 192.4M
- IPO Year
- INZY 2020
- CCRD N/A
- Fundamental
- Price
- INZY $1.60
- CCRD $22.44
- Analyst Decision
- INZY Strong Buy
- CCRD Hold
- Analyst Count
- INZY 8
- CCRD 1
- Target Price
- INZY $17.75
- CCRD $15.00
- AVG Volume (30 Days)
- INZY 666.9K
- CCRD 55.2K
- Earning Date
- INZY 11-05-2024
- CCRD 02-12-2025
- Dividend Yield
- INZY N/A
- CCRD N/A
- EPS Growth
- INZY N/A
- CCRD 6.70
- EPS
- INZY N/A
- CCRD 0.49
- Revenue
- INZY N/A
- CCRD $54,733,000.00
- Revenue This Year
- INZY N/A
- CCRD $1.95
- Revenue Next Year
- INZY N/A
- CCRD $12.19
- P/E Ratio
- INZY N/A
- CCRD $46.70
- Revenue Growth
- INZY N/A
- CCRD N/A
- 52 Week Low
- INZY $1.62
- CCRD $10.02
- 52 Week High
- INZY $7.80
- CCRD $24.97
- Technical
- Relative Strength Index (RSI)
- INZY 22.68
- CCRD 52.75
- Support Level
- INZY $2.68
- CCRD $21.61
- Resistance Level
- INZY $3.18
- CCRD $23.98
- Average True Range (ATR)
- INZY 0.27
- CCRD 0.93
- MACD
- INZY -0.11
- CCRD -0.15
- Stochastic Oscillator
- INZY 1.87
- CCRD 44.30
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About CCRD CoreCard Corporation
CoreCard Corp is engaged in the business of providing technology solutions and processing services to the financial technology and services market. It designs, develops and markets a comprehensive suite of software solutions to program managers, accounts receivable businesses, financial institutions, retailers and processors to manage their credit and debit cards, prepaid cards, private label cards, fleet cards, buy now pay later programs, loyalty programs and accounts receivable and loan transactions. The CoreCard software platform and modules include CoreENGINE, CoreISSUE, CoreFRAUD, CoreCOLLECT, CoreAPP, CoreMONEY and CoreACQUIRE. Its customers are located in the U.S, European Union and the Middle East of which key revenue is derived from the U.S.